BALAXI PHARMACEUTICALS enterprise value

·UnclassifiedChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
113————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
14.614.639.462.328.2
55.855.851.617.711.6
154————
41.241.212.2−44.6−16.6
₹27.98————
305305283219195
18.3%18.3%18.2%8.1%6.0%
0.36×————
0.55×————
17.08×————
23.75×————
Reference items — trailing FY values
280270293241336
9.08.537.246.756.5
6.56.435.344.654.8
—−4.5−35.04.96.1
−19.4−19.4−36.44.2−4.7
—−21.6−36.73.3−4.8
—14.91.40.710.8
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BALAXI₹20.51

BALAXI PHARMACEUTICALS LIMITED

· Unclassified
₹ CrorePeersPARSTEELCITYLATTEYSCROWNHECPROJECTHINDCONAIROLAMGROBTEAMcap ₹113 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————113.2
- Cash, Equiv & ST Investments28.262.339.414.614.6
+ Total Debt11.617.751.655.855.8
Enterprise Value————154.5
Net Debt (memo)-16.6-44.612.241.241.2
EV per Share————27.98
Total Capital194.5219.0283.4304.9304.9
Total Debt/Total Capital5.978.0618.2218.3018.30
Total Debt/EV————0.36
EV/Sales————0.55
EV/EBITDA————17.08
EV/EBIT————23.75
Reference Items — Trailing FY Values
Sales336.4241.3292.6270.2280.1
EBITDA56.546.737.28.59.0
EBIT54.844.635.36.46.5
Operating Cash Flow6.14.9-35.0-4.5—
Free Cash Flow-4.74.2-36.4-19.4-19.4
FCFF (free cash flow to the firm)-4.83.3-36.7-21.6—
Capital Expenditure10.80.71.414.9—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.